Fig. 1. Gata6 deletion impairs LUAD progression in Kras^LSL-G12D (K) and Kras^LSL-G12Dp53 ^fl/fl (KP) mouse models.

a Immunohistochemistry of GATA6 in K and KP GEMMs at different stages of LUAD progression. Scale bar = 100 μm. b Left, H&E of tumor-bearing lungs from K and KG mice at 50 weeks post infection with Ad-Cre. Right, quantification of tumor burden (total tumor area) per lung (n = 3–5 mice). c Left, lung tumor burden of K and KG mice measured by bioluminescence at 50 and 91 days post infection with Lenti-Cre (n = 5–6 mice). Right, representative bioluminescent pictures from day 91. d Left, H&E of tumor-bearing lungs from KP and KPG mice at 12 weeks post infection with Ad-Cre. Right, quantification of tumor burden (total tumor area) per lung (n = 6–10 mice). e Left, lung tumor burden of KP and KPG mice measured by bioluminescence at 50 and 90 days post infection with Lenti-Cre (n = 4 mice). Right, representative bioluminescent pictures from day 90. Unless indicated, data were plotted with standard error of the mean (SEM). P value was calculated by unpaired t-test, except for day 50 of e (Mann–Whitney) and c (Welch’s t-test). Total tumor area was measured per lung and per mouse, and was normalized to K or KP controls.